Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1606

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 1606
---
ous cell therapies,
we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are
required by regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in the initiation
and completion of our clinical trials or the development of any of our product candidates, our expenses could increase and profitability
could be further delayed.

Even if we achieve profitability,
we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would
depress the value of our securities and could impair our ability to raise capital, expand our business, maintain our R&D efforts or
continue our operations. A decline in the value of our securities could also cause you to lose all or part of your investment.

There is substantial doubt as to our ability
to continue as a going concern.

As of December 31, 2024, the Company reported
$3.3 million of cash and cash equivalents, with an accumulated deficit of $70.9 million. Additional funds are necessary to maintain current
operations and to continue R&D activities. However, there can be no assurance that sufficient funding will be available to allow the
Company to successfully continue its R&D activities and planned regulatory filings with the FDA. If the Company is unable to obtain
the necessary funds, significant reductions in spending and the delay or cancellation of planned activities may be necessary. These actions
would have a material adverse effect on the Company’s business, results of operations, and prospects. These conditions raise substantial
doubt about the Company’s ability to continue as a going concern within one year from the date these accompanying financial statements
are issued. In its report on our financial statements for the year ended December 31, 2024, our independent registered public accounting
firm included an explanatory paragraph that expressed substantial doubt about our ability to continue as a going concern. Our current
cash level raises substantial doubt about our ability to continue as a going concern. In addition, our future financial statements may
include similar qualifications about our ability to continue as a going concern. Our financial statements were prepared assuming that
we will continue as a going concern and do not include any adjustments that may result from the outcome of this uncertainty. If we are
unable to meet our current operating costs, we will need to seek additional financing or modify or cease our operational plans. If we
seek additional financing to fund our business activities in the future and there